Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06361316
NA
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Sponsor: Kuirong Jiang
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Official title: Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
53
Start Date
2024-04-08
Completion Date
2028-07-31
Last Updated
2024-04-11
Healthy Volunteers
No
Conditions
Interventions
DRUG
Irinotecan liposome injection
Postoperative adjuvant therapy
Locations (1)
FirstNanjingMU
Nanjing, Jiangsu, China